JP2023507816A - がんを治療するための方法及び組成物 - Google Patents

がんを治療するための方法及び組成物 Download PDF

Info

Publication number
JP2023507816A
JP2023507816A JP2022538286A JP2022538286A JP2023507816A JP 2023507816 A JP2023507816 A JP 2023507816A JP 2022538286 A JP2022538286 A JP 2022538286A JP 2022538286 A JP2022538286 A JP 2022538286A JP 2023507816 A JP2023507816 A JP 2023507816A
Authority
JP
Japan
Prior art keywords
ron
src
gene
cases
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022538286A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023507816A5 (https=
Inventor
キム，タックフーン
ルー，ティモシー
ハリソン，スティーブン
テイラー ブリュー，クリスティーン
アンダーソン，グレース
バロン，シルヴァン
ペ，ジェシー
ヨスト，ショーン
パーセル，オリバー
チャン，シッティング
クライン，トニ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Massachusetts Institute of Technology
Original Assignee
Massachusetts Institute of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Institute of Technology filed Critical Massachusetts Institute of Technology
Publication of JP2023507816A publication Critical patent/JP2023507816A/ja
Publication of JP2023507816A5 publication Critical patent/JP2023507816A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022538286A 2019-12-20 2020-12-16 がんを治療するための方法及び組成物 Pending JP2023507816A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962951479P 2019-12-20 2019-12-20
US62/951,479 2019-12-20
US202063114930P 2020-11-17 2020-11-17
US63/114,930 2020-11-17
PCT/US2020/065335 WO2021126995A1 (en) 2019-12-20 2020-12-16 Methods and compositions for treating cancer

Publications (2)

Publication Number Publication Date
JP2023507816A true JP2023507816A (ja) 2023-02-27
JP2023507816A5 JP2023507816A5 (https=) 2023-12-26

Family

ID=76478290

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022538286A Pending JP2023507816A (ja) 2019-12-20 2020-12-16 がんを治療するための方法及び組成物

Country Status (4)

Country Link
US (1) US20220356494A1 (https=)
EP (1) EP4077690A4 (https=)
JP (1) JP2023507816A (https=)
WO (1) WO2021126995A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240398799A1 (en) * 2021-08-19 2024-12-05 Engine Biosciences Pte. Ltd. Compositions and methods for generating synthetic lethality in tumors
WO2023205463A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2024134516A1 (ko) * 2022-12-23 2024-06-27 주식회사 엘지화학 Ron 억제제로서 신규한 화합물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008147687A1 (en) * 2007-05-21 2008-12-04 Mayo Foundation For Medical Education And Research Treating pancreatitis
JP6342392B2 (ja) * 2012-07-28 2018-06-13 カリター・サイエンシーズ・エルエルシー 置換型ピラゾロン化合物及び使用方法
US9694084B2 (en) * 2014-12-23 2017-07-04 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
KR20190039115A (ko) * 2016-07-05 2019-04-10 더 존스 홉킨스 유니버시티 암을 치료하기 위한 crispr/cas9-기반 조성물 및 방법
US20210139889A1 (en) * 2017-06-19 2021-05-13 Yale University Compositions and Methods for Multiplexed Genome Editing and Screening
WO2019014390A1 (en) * 2017-07-12 2019-01-17 Refuge Biotechnologies, Inc. METHODS AND SYSTEMS FOR CONDITIONAL REGULATION OF GENE EXPRESSION
WO2019197605A2 (en) * 2018-04-12 2019-10-17 Umc Utrecht Holding B.V. Drug combinations for use in the treatment of ras-mutant cancer
CA3139969A1 (en) * 2019-06-20 2020-12-24 Dana-Farber Cancer Institute, Inc. Small molecule inhibitors of src tyrosine kinase

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, vol. 200, no. 7, JPN6025008976, 1 October 2019 (2019-10-01), pages 888 - 899, ISSN: 0005542790 *
BONE, vol. 113, JPN6025008973, 2018, pages 95 - 104, ISSN: 0005542793 *
CELLULAR SIGNALLING, vol. 24, no. 6, JPN6025008981, 2012, pages 1276 - 1286, ISSN: 0005542785 *
INTERNATIONAL JOURNAL OF CANCER, vol. 122, no. 9, JPN6025008977, 2008, pages 1999 - 2007, ISSN: 0005542789 *
JOURNAL OF MEDICINAL CHEMISTRY, vol. 47, no. 27, JPN6025008980, 2004, pages 6658 - 6661, ISSN: 0005542786 *
MOLECULAR AND CELLULAR BIOLOGY, vol. 20, no. 23, JPN6025008979, 2000, pages 9018 - 9027, ISSN: 0005542787 *
PLOS ONE, vol. Vol. 10, No. 3, e0118854, JPN6025008975, 2015, pages 1 - 16, ISSN: 0005542791 *
PLOS ONE, vol. Vol. 6, No. 4, e19309, JPN6025008978, 2011, pages 1 - 11, ISSN: 0005542788 *
PROTEIN EXPRESSION AND PURIFICATION, vol. 19, no. 1, JPN6025008974, 2000, pages 99 - 106, ISSN: 0005542792 *

Also Published As

Publication number Publication date
WO2021126995A1 (en) 2021-06-24
US20220356494A1 (en) 2022-11-10
EP4077690A1 (en) 2022-10-26
EP4077690A4 (en) 2024-04-10

Similar Documents

Publication Publication Date Title
Yuan et al. Discovery of new 4-indolyl quinazoline derivatives as highly potent and orally bioavailable P-glycoprotein inhibitors
Samarin et al. PI3K/AKT/mTOR‐dependent stabilization of oncogenic far‐upstream element binding proteins in hepatocellular carcinoma cells
US20230149415A1 (en) Methods and compositions for treating cancer
EP3160463B1 (en) Intermittent dosing of mdm2 inhibitor
US11666580B2 (en) Mechanism of resistance to bet bromodomain inhibitors
EP3678703A1 (en) Shp2 inhibitor compositions and methods for treating cancer
US20150045370A1 (en) Sik inhibitor for use in a method of treating an inflammatory and/or immune disorder
US20220356494A1 (en) Methods and compositions for treating cancer
Ge et al. Phosphodiesterase 4D acts downstream of Neuropilin to control Hedgehog signal transduction and the growth of medulloblastoma
AU2014246667A1 (en) Methods of treating diseases characterized by excessive Wnt signalling
JP2014533294A (ja) ホスホイノシチド３−キナーゼ阻害剤およびヤヌスキナーゼ２−シグナル伝達兼転写活性化因子５経路の調節剤の組合せ
CN110035749B (zh) Fabp4作为皮肤病中的治疗靶
US20120294956A1 (en) Inhibition of dynamin related protein 1 to promote cell death
Li et al. Discovery, synthesis, and evaluation of novel dual inhibitors of a vascular endothelial growth factor receptor and poly (Adp-ribose) polymerase for brca wild-type breast cancer therapy
US20140371233A1 (en) COMPOSITIONS AND METHODS FOR TREATING Aß-MODULATED DISEASE OR DISORDER OR IMPROVING COGNITION IN A SUBJECT
US11980628B2 (en) Prostate cancer treatment via synergistic inhibition of aryl hydrocarbon receptor (AhR) and SRC
CN113559267B (zh) 细胞死亡诱导试剂、细胞增殖抑制试剂及用于治疗由细胞增殖异常导致的疾病的医药组合物
US9545396B2 (en) Method and pharmaceutical composition for inhibiting PI3K/AKT/mTOR signaling pathway
US9750728B2 (en) Method and pharmaceutical composition for inhibiting PI3K/AKT/mTOR signaling pathway
HK1231740B (en) Intermittent dosing of mdm2 inhibitor
HK1231740A1 (en) Intermittent dosing of mdm2 inhibitor
HK1244482A1 (zh) 用於治疗神经母细胞瘤的组合

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231218

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231218

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250305

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250827